自膨胀瓣膜经导管主动脉瓣置换术用于低风险患者
该随机非劣效性试验纳入1468例低外科风险的重度主动脉瓣狭窄患者,比较自膨胀瓣膜TAVR与外科主动脉瓣置换术。850例完成12个月随访时,采用贝叶斯方法分析24个月死亡或致残性卒中的复合终点。TAVR组24个月主要终点估计发生率为5.3%,手术组为6.7%,差异为-1.4个百分点(95%贝叶斯可信区间-4.9至2.1),非劣效后验概率>0.999。30天时TAVR组致残性卒中、出血并发症、急性肾损伤和心房颤动发生率更低,但中重度主动脉瓣反流和起搏器植入发生率更高。
要点
- 低外科风险重度主动脉瓣狭窄患者中,TAVR组24个月死亡或致残性卒中估计发生率为5.3%,手术组为6.7%,差异-1.4个百分点(95%贝叶斯可信区间-4.9至2.1),非劣效后验概率>0.999。
- 30天时TAVR组致残性卒中发生率为0.5%,手术组为1.7%。
- 30天时TAVR组出血并发症发生率为2.4%,手术组为7.5%;急性肾损伤发生率为0.9%,手术组为2.8%。
- 30天时TAVR组中重度主动脉瓣反流发生率为3.5%,手术组为0.5%;起搏器植入发生率为17.4%,手术组为6.1%。
- 12个月时TAVR组主动脉瓣跨瓣压差为8.6 mm Hg,手术组为11.2 mm Hg;有效瓣口面积TAVR组为2.3 cm2,手术组为2.0 cm2。
适用人群与场景
- 重度主动脉瓣狭窄且低外科风险的患者,平均年龄74岁。
- 随机分组1468例,其中1403例实际尝试了TAVR或外科手术。
研究设计与关键结果
- 随机非劣效性试验,1468例患者随机分组,1403例尝试TAVR或外科手术,比较自膨胀环上生物瓣膜TAVR与外科主动脉瓣置换术。
- 主要终点为24个月死亡或致残性卒中的复合终点,TAVR组估计发生率5.3%,手术组6.7%,差异-1.4个百分点(95%贝叶斯可信区间-4.9至2.1),非劣效后验概率>0.999。
- 30天致残性卒中:TAVR组0.5% vs 手术组1.7%;出血并发症:TAVR组2.4% vs 手术组7.5%;急性肾损伤:TAVR组0.9% vs 手术组2.8%;心房颤动:TAVR组7.7% vs 手术组35.4%。
- 30天中重度主动脉瓣反流:TAVR组3.5% vs 手术组0.5%;起搏器植入:TAVR组17.4% vs 手术组6.1%。
- 12个月主动脉瓣跨瓣压差:TAVR组8.6 mm Hg vs 手术组11.2 mm Hg;有效瓣口面积:TAVR组2.3 cm2 vs 手术组2.0 cm2。
证据类型、等级与局限
- 证据类型:随机非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于低外科风险的重度主动脉瓣狭窄患者,使用自膨胀瓣膜行TAVR在24个月死亡或致残性卒中复合终点上不劣于外科手术。
- TAVR组30天致残性卒中、出血并发症、急性肾损伤和心房颤动发生率更低,但中重度主动脉瓣反流和起搏器植入发生率更高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis who are at increased risk for death from surgery; less is known about TAVR in low-risk patients.
METHODS: We performed a randomized noninferiority trial in which TAVR with a self-expanding supraannular bioprosthesis was compared with surgical aortic-valve replacement in patients who had severe aortic stenosis and were at low surgical risk. When 850 patients had reached 12-month follow-up, we analyzed data regarding the primary end point, a composite of death or disabling stroke at 24 months, using Bayesian methods.
RESULTS: Of the 1468 patients who underwent randomization, an attempted TAVR or surgical procedure was performed in 1403. The patients' mean age was 74 years. The 24-month estimated incidence of the primary end point was 5.3% in the TAVR group and 6.7% in the surgery group (difference, -1.4 percentage points; 95% Bayesian credible interval for difference, -4.9 to 2.1; posterior probability of noninferiority >0.999). At 30 days, patients who had undergone TAVR, as compared with surgery, had a lower incidence of disabling stroke (0.5% vs. 1.7%), bleeding complications (2.4% vs. 7.5%), acute kidney injury (0.9% vs. 2.8%), and atrial fibrillation (7.7% vs. 35.4%) and a higher incidence of moderate or severe aortic regurgitation (3.5% vs. 0.5%) and pacemaker implantation (17.4% vs. 6.1%). At 12 months, patients in the TAVR group had lower aortic-valve gradients than those in the surgery group (8.6 mm Hg vs. 11.2 mm Hg) and larger effective orifice areas (2.3 cm2 vs. 2.0 cm2).
CONCLUSIONS: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months. (Funded by Medtronic; ClinicalTrials.gov number, NCT02701283.).
参考来源
- Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019. PMID: 30883053. doi:10.1056/NEJMoa1816885
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。